Physician profile
Keith Freeman
NPI 1003357948
$2,167.08
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $251 · 2021: $699 · 2022: $664 · 2023: $521 · 2024: $30.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $552.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $346.67 | 2020-2023 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $331.73 | 2020-2023 | Synjardy, Jardiance, Tradjenta |
| Dexcom, INC. | $264.31 | 2020-2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $198.35 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $104.28 | 2021-2023 | |
| Astrazeneca Pharmaceuticals Lp | $90.11 | 2020-2022 | |
| Amgen INC. | $84.74 | 2020-2021 | |
| Daiichi Sankyo INC. | $77.75 | 2021-2022 | |
| Lilly USA, LLC | $77.44 | 2021-2023 | Mounjaro, Jardiance |
| Sanofi-Aventis U.S. LLC | $65.90 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.26 | 2021-2022 | |
| Lundbeck LLC | $54.12 | 2023 | Vyepti |
| Pfizer INC. | $48.09 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $46.57 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $41.59 | 2022-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $38.72 | 2021 | |
| Amarin Pharma, INC. | $36.20 | 2020-2022 | |
| Ibsa Pharma INC. | $28.75 | 2022-2023 | Tirosint, Licart |
| Exact Sciences Corporation | $27.49 | 2023 | Cologuard Collection Kit |
| Inari Medical, INC. | $25.42 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Esperion Therapeutics, INC. | $24.40 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.71 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $15.64 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.89 | 2022 | |
| Acadia Pharmaceuticals INC | $14.65 | 2021 | |
| Shield Therapeutics INC | $12.43 | 2022 | |
| Almatica Pharma LLC | $11.52 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.